Dr Andrew Bell: Ledger

Stories naming Dr Andrew Bell. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.

Role	Organisation	Sources
	Pfizer	Brandon Capital portfolio, Brandon BioCatalyst portfolio
Chemistry Consultant · Founder	Myricx Pharma	Brandon Capital portfolio, Brandon BioCatalyst portfolio

Seed $8.2m

Myricx Pharma Launches with £4.5M (AU$8.2M) Financing to Progress its Novel NMT inhibitors in Cancer

UK biotech Myricx Pharma launched with a £4.5 million seed round from Sofinnova Partners and Brandon Capital to advance its NMT-inhibitor cancer drug discovery work.

Brandon BioCatalyst portfolio Mon 16 Nov 2020 Myricx Pharma Charles Consultants GSK Heptares Medical Research Commercialisation Fund (MRCF)Pfizer Brandon Capital Partners Sofinnova Partners Dr Andrew Bell Prof Ed Tate Maina Bhaman Dr Roberto Solari Dr Robin Carr Dr Stephen Thompson Sue Charles

Also Brandon Capital portfolio·Brandon BioCatalyst portfolio·Brandon Capital portfolio

Dr Andrew Bell

Roles

Coverage

Myricx Pharma Launches with £4.5M (AU$8.2M) Financing to Progress its Novel NMT inhibitors in Cancer